BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

Evive planning BLA, MAA for neutropenia therapy following pivotal trial readout  Evive Biotech Inc. said efbemalenograstim alfa met the primary and secondary endpoints in a Phase III study to prevent chemotherapy-induced neutropenia in breast cancer...
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

CHMP backs Ebola vaccine, targeted cancer therapies  EMA’s CHMP recommended approval of a two-component Ebola vaccine -- Zabdeno and Mvabea -- from Johnson & Johnson (NYSE:JNJ) Friday. The agency also backed two targeted cancer therapies:...
BC Extra | Apr 26, 2019
Company News

Soriot sees progress in U.S.-China IP debate

AstraZeneca CEO Pascal Soriot said China is making progress on protecting biopharma IP, as the pharma reported 1Q19 earnings that saw a 28% increase year-over-year in sales in the country. "Everything we've seen happening over...
BC Week In Review | Mar 1, 2019
Clinical News

Brilinta reduces CV events in patients without prior heart attack, stroke

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor met the primary endpoint of reducing major adverse cardiovascular events (MACE) in the Phase III THEMIS trial in patients with coronary artery disease and Type II diabetes with...
BC Extra | Feb 25, 2019
Clinical News

Brilinta reduces CV events in patients without prior heart attack, stroke

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor met the primary endpoint of reducing major adverse cardiovascular events (MACE) in the Phase III THEMIS trial in patients with coronary artery disease and Type II diabetes with...
BC Week In Review | Feb 1, 2019
Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
BC Extra | Jan 28, 2019
Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
BC Week In Review | Nov 9, 2018
Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...
BC Extra | Nov 8, 2018
Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Thursday it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates from...
BC Week In Review | Oct 19, 2018
Financial News

PhaseBio, Osmotica price NASDAQ IPOs well below range

Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced IPOs well below their proposed ranges late Oct. 17. PhaseBio trading ended flat at $5 on Oct....
Items per page:
1 - 10 of 145